Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities
Reads0
Chats0
TLDR
This review mentions several possible additional therapeutic targets for cannabinoid receptor agonists and describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic.Abstract:
Human tissues express cannabinoid CB(1) and CB(2) receptors that can be activated by endogenously released 'endocannabinoids' or exogenously administered compounds in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy. Three medicines that activate cannabinoid CB(1)/CB(2) receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ(9)-tetrahydrocannabinol (Δ(9)-THC)) and Sativex (Δ(9)-THC with cannabidiol). These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (Cesamet and Marinol), stimulation of appetite (Marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (Sativex). This review mentions several possible additional therapeutic targets for cannabinoid receptor agonists. These include other kinds of pain, epilepsy, anxiety, depression, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders. It also describes potential strategies for improving the efficacy and/or benefit-to-risk ratio of these agonists in the clinic. These are strategies that involve (i) targeting cannabinoid receptors located outside the blood-brain barrier, (ii) targeting cannabinoid receptors expressed by a particular tissue, (iii) targeting upregulated cannabinoid receptors, (iv) selectively targeting cannabinoid CB(2) receptors, and/or (v) adjunctive 'multi-targeting'.read more
Citations
More filters
Journal ArticleDOI
Modulating the endocannabinoid system in human health and disease--successes and failures.
Pal Pacher,George Kunos +1 more
TL;DR: Clinical trials with globally acting CB1 antagonists in obesity/metabolic syndrome, and other studies with peripherally‐restricted CB1/2 agonists and inhibitors of the endocannabinoid metabolizing enzyme in pain, have introduced unexpected complexities, suggesting that a better understanding of the pathophysiological role of the ENDOCannabinoid system is required to devise clinically successful treatment strategies.
Journal ArticleDOI
The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances.
TL;DR: MMLs have no discernible impact on drinking behavior for those aged 12-20, or the use of other psychoactive substances in either age group, but increase in the probability of current marijuana use, regular marijuana use and marijuana abuse/dependence among those aged 21 or above.
Journal ArticleDOI
Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation
Ismael Galve-Roperh,Valerio Chiurchiù,Javier Díaz-Alonso,Monica Bari,Manuel Guzmán,Mauro Maccarrone +5 more
TL;DR: Endocannabinoid (eCB) signaling has been shown to regulate proliferation and differentiation of mesoderm-derived hematopoietic and mesenchymal stem cells, with a key role in determining the formation of several cell types in peripheral tissues, including blood cells, adipocytes, osteoblasts/osteoclasts and epithelial cells.
Journal ArticleDOI
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Miriam Mecha,Ana Feliú,Paula M. Iñigo,Leyre Mestre,Francisco J. Carrillo-Salinas,Carmen Guaza +5 more
TL;DR: Using this viral model of multiple sclerosis (MS), it is demonstrated that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1, chemokines and the proinflammatory cytokine IL-1β, as well as by attenuating the activation of microglia.
Journal ArticleDOI
Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling
Barna Dudok,László Barna,Marco Ledri,Szilárd I. Szabó,Eszter Szabadits,Balazs Pinter,Stephen G. Woodhams,Christopher M. Henstridge,Gyula Y. Balla,Gyula Y. Balla,Rita Nyilas,Csaba Varga,Sang-Hun Lee,Máté Matolcsi,Judit Cervenak,Imre Kacskovics,Masahiko Watanabe,Claudia Sagheddu,Miriam Melis,Marco Pistis,Ivan Soltesz,István Katona +21 more
TL;DR: It is found that axon terminals of perisomatically projecting GABAergic interneurons possessed increased CB1 receptor number, active-zone complexity and receptor/effector ratio compared with dendritically projecting interneURons, consistent with higher efficiency of cannabinoid signaling at somatic versus dendritic synapses.
References
More filters
Journal ArticleDOI
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
TL;DR: This review focuses on the manner with which three of these compounds, (−)‐trans‐Δ 9‐tetrahydrocannabinol (Δ9‐THC), (−]‐cannabidiol (CBD) and (−)-trans‐ Δ9‐TetrahYDrocannabivarin (Γ‐THCV), interact with cannabinoid CB1 and CB2 receptors.
Journal ArticleDOI
Cannabinoid receptors and pain.
TL;DR: The evidence firstly that one endogenous cannabinoid, anandamide, produces antinociception through mechanisms that differ from those of other types of cannabinoid, for example by acting on vanilloid receptors, and secondly that the endocannabinoid system has physiological and/or pathophysiological roles in the modulation of pain is discussed.
Journal ArticleDOI
Cannabinoids: potential anticancer agents
TL;DR: Cannabinoids — the active components of Cannabis sativa and their derivatives — exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite.
Journal ArticleDOI
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Sabine Steffens,Niels R. Veillard,Claire Arnaud,Graziano Pelli,Fabienne Burger,Christian Staub,Andreas Zimmer,Jean-Louis Frossard,François Mach +8 more
TL;DR: Oral treatment with a low dose of THC inhibits atherosclerosis progression in the apolipoprotein E knockout mouse model through pleiotropic immunomodulatory effects on lymphoid and myeloid cells, demonstrating that THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating Atherosclerosis.
Journal ArticleDOI
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
TL;DR: Five strategies that have the potential to meet either the efficacy and/or the benefit‐to‐risk ratio of a cannabinoid receptor agonist are focused on.